IAM
KURA icon

Innovis Asset Management’s Kura Oncology KURA Stock Holding History

Innovis Asset Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,443
Closed -$164K – 178
2023
Q1 		$164K Buy
13,443
+39
+0.3% +$487 0.07% 150
2022
Q4 		$166K Buy
+13,404
New +$195K 0.08% 144

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Innovis Asset Management's KURA Position: Q2 2023 in Review

Innovis Asset Management sold out of Kura Oncology (KURA) in Q2 2023, closing a stake of 13,443 shares — an estimated $164K sold.

Innovis Asset Management first reported a position in KURA in Q4 2022 and held it in 2 quarters. The position peaked at $166K in Q4 2022. 148 funds tracked by Wall St. Rank hold KURA as of Q2 2023.

  • Innovis Asset Management reported no remaining Kura Oncology position as of Q2 2023 after selling out during the quarter.
  • Innovis Asset Management sold 13,443 Kura Oncology shares in Q2 2023, an estimated $164K.
  • Innovis Asset Management first reported a position in Kura Oncology in Q4 2022 and held it in 2 quarters.
  • Innovis Asset Management's Kura Oncology position peaked at $166K in Q4 2022.
  • 148 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2023.

Based on Innovis Asset Management's 13F filing for Q2 2023, filed 3 Aug 2023.